All In Biotech

Drugs by condition

Drugs approved for chronic myeloid leukemia

Brand-name prescription drugs and biologics whose FDA label lists chronic myeloid leukemia as an approved use. Matched on the label phrases: "chronic myeloid leukemia", "Philadelphia chromosome".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

13

Still marketed, NDA or BLA

Drug classes

3

Novel drugs

7

New molecular entities and new biologics

In development

6

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for chronic myeloid leukemia.

  • Cavhanza (Nilotinib) · Cycle OrphanMay 29, 2026
  • Imkeldi (Imatinib Mesylate) · Shorla Oncology Nov 22, 2024
  • Danziten (Nilotinib Tartrate) · Azurity Nov 7, 2024
  • Phyrago (Dasatinib) · Handa Therap OrphanDec 5, 2023
  • Bosulif (Bosutinib Monohydrate) · Pf Prism Cv Priority reviewOrphanSep 26, 2023

All approved drugs for chronic myeloid leukemia, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 29 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Kinase Inhibitor (2)

  • Cavhanza Nilotinib · Cycle · 2026
  • Danziten Nilotinib Tartrate · Azurity · 2024

Antimetabolite (1)

  • Droxia Hydroxyurea · Waylis Therap · 1967

Class not listed in FDA's data (10)

  • Scemblix Asciminib Hydrochloride · Novartis · 2021
  • Blincyto Blinatumomab · Amgen · 2014
  • Iclusig Ponatinib Hydrochloride · Takeda Pharms USA · 2012
  • Bosulif Bosutinib Monohydrate · Pf Prism Cv · 2012
  • Tasigna Nilotinib Hydrochloride · Novartis · 2007
  • Sprycel Dasatinib · Bristol Myers Squibb · 2006
  • Imkeldi Imatinib Mesylate · Shorla Oncology · 2024
  • Phyrago Dasatinib · Handa Therap · 2023
  • Bosulif Bosutinib Monohydrate · Pf Prism Cv · 2023
  • Gleevec Imatinib Mesylate · Novartis · 2003

Drugs in development for chronic myeloid leukemia

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • OlverembatinibPhase 34 trials

    Ascentage Pharma Group Inc. · Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed/Refractory Acute Myeloid Leukaemia

  • RadotinibSupect, IY5511Phase 33 trials

    Il-Yang Pharm. Co., Ltd. · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory

  • HS-10382MK-4208, Tern-701Phase 32 trials

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase

  • TGRX-678Phase 32 trials

    Shenzhen TargetRx Co., Ltd. · Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myeloid Leukemia

  • ELVN-001Phase 31 trial

    Enliven Therapeutics · Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML

  • FlumatinibPhase 31 trial

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · Chronic Myeloid Leukemia

1 discontinued brand-name drugs whose label still names it

More on chronic myeloid leukemia: recruiting trials · published research

Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease · Hemophilia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.